Skip to main content

Year: 2025

Additional Confirmed Response Reported as Part of Amplia Investor Presentation

HIGHLIGHTSAn additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate to 35%Updated data to be presented at the Life Sciences Virtual Investor ForumMelbourne, Australia, Dec. 12, 2025 (GLOBE NEWSWIRE) — Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announce that an additional confirmed partial response (PR) has been recorded in the ongoing ACCENT trial in metastatic pancreatic cancer. The trial investigates the combination of the Company’s best-in-class FAK inhibitor narmafotinib in combination with the chemotherapies gemcitabine and nab-paclitaxel (Abraxane®). The additional PR brings the confirmed objective response rate (ORR) to 35% (19/55) which compares favourably to the ORR of 23% recorded for...

Continue reading

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization in the European Union (EU) for MYQORZO® (aficamten), a cardiac myosin inhibitor, for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. A final decision is anticipated from the European Commission in the first quarter of 2026. “We are pleased with CHMP’s positive recommendation based on the robust clinical evidence from SEQUOIA-HCM that demonstrated the safety and efficacy of MYQORZO in patients...

Continue reading

Rail Vision: Quantum AI Powers Next-Gen Rail Safety Breakthroughs

Rail Vision Enters the Quantum Transportation Market with Strategic Acquisition Agreement  Ra’anana, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) — Rail Vision Ltd. (Nasdaq: RVSN) (“Rail Vision” or the “Company”), an early commercialization stage technology company seeking to revolutionize railway safety and the data-related market, recently announced the signing of an agreement for a strategic transaction to acquire 51% ownership of Quantum Transportation Ltd. (the “Acquisition” and “Quantum Transportation”), a cutting-edge quantum computing and AI company specializing in error correction technologies. The closing of the Acquisition is expected to close in late December 2025 to early January 2026, subject to the satisfaction of customary closing conditions. Quantum Transportation holds an exclusive sublicense, for rail technologies...

Continue reading

WELLE Environmental Group and Primech Holdings Enter Strategic Cooperation to Advance Intelligent Industrial Robotics and Sustainable Operations

Advancing Intelligent Operations and Sustainable Solutions Across Complex Industrial Environments SINGAPORE, Dec. 12, 2025 (GLOBE NEWSWIRE) — WELLE Environmental Group Co., Ltd. (300190.SZ) (“WELLE”), a leading energy-saving and environmental technology enterprise in China, and Primech Holdings Ltd. (“Primech Holdings”), a Singapore-based provider of technology-driven facilities services (Nasdaq: PMEC), today announced the signing of a Strategic Cooperation Framework Agreement to jointly accelerate innovation in industrial robotics, intelligent operations, and sustainable environmental technologies. Under the agreement, both parties will establish a Joint Venture in Singapore, combining WELLE’s industry-leading capabilities in environmental governance and bioenergy with Primech Holdings’ extensive operational experience and its...

Continue reading

Clearmind Medicine’s MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

Vancouver, Canada, Dec. 12, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of a review article validating the therapeutic promise of its proprietary candidate, MEAI (5-methoxy-2-aminoindane, also known as CMND-100), in combating alcohol use disorder (AUD). Entitled “The Potential Therapeutic Effects of MEAI in the Treatment of Alcohol Use Disorder“, the peer-reviewed review was published on December 2, 2025, in Current Addiction Reports, a respected Springer Nature journal advancing evidence-based addiction research. Authored by a group of experts led...

Continue reading

VisionWave Holdings, Inc. Announces Intention to Launch Up to £500,000 Autonomous Ground Vehicle Program with Evie Autonomous

Discussions Began in August 2025 as VisionWave Expanded London-Based UGV R&D Capabilities WEST HOLLYWOOD, Calif. and LONDON, Dec. 12, 2025 (GLOBE NEWSWIRE) — VisionWave Holdings, Inc. (Nasdaq: VWAV) (“VisionWave” or the “Company”), a U.S.-based company focused on next-generation defense, autonomy, and RF-driven perception technologies, today announced that it has entered into a non-binding letter of intent with Evie Autonomous Limited, a UK developer of advanced autonomous mobility systems, to explore the potential for a £500,000 Proof-of-Concept (POC) program integrating Evie’s autonomous vehicle technology into VisionWave’s Unmanned Ground Vehicle (UGV) platforms, subject to the negotiation and execution of definitive agreements. This initiative reflects months of structured engagement between the companies. Discussions...

Continue reading

NewGen to Exercise Option to Convert Ras Al Khaimah Joint Venture into Joint Development, Projected to Boost Profits from US$67 Million to US$123 Million

Strategic Move to Unlock Further Value and Accelerate Project Momentum with Planned Fundraising and Upcoming Presale Launch BANGKOK, Dec. 12, 2025 (GLOBE NEWSWIRE) — NewGenIVF Group Limited (“NewGen” or the “Company,” NASDAQ: NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today announced its intention to exercise an option under its joint venture agreement (“JVA”) with BNW Real Estate Development LLC (“BNW”) to convert the Ras Al Khaimah development project from a Joint Venture structure into a Joint Development structure, while maintaining the existing shareholding of the special purpose vehicle (“SPV”). This strategic conversion is expected to enhance NewGen’s profit entitlement in the flagship Ras Al Khaimah Beach District luxury project,...

Continue reading

BitFuFu Named to World Future Awards’ TOP 100 Next Generation Companies for 2025

SINGAPORE, Dec. 12, 2025 (GLOBE NEWSWIRE) — BitFuFu Inc. (“BitFuFu” or the “Company”) (Nasdaq: FUFU), a world-leading Bitcoin miner and mining services innovator, has been named one of the World Future Awards’ TOP 100 Next Generation Companies of 2025, a global honor recognizing organizations shaping the future through excellence, innovation, and positive impact. In an official congratulatory letter issued by the World Future Awards Organizing Committee, the panel commended BitFuFu for its “dedication to innovation and excellence,”. They added that the Company “embodies the highest standards of creativity, effectiveness, and influence in shaping the future of its field.” The TOP 100 Next Generation Companies Award recognizes leading innovators whose contributions are driving global technological and economic progress. Other awardees...

Continue reading

Norwood Financial Corp Announces Receipt of Regulatory Approvals for Acquisition of PB Bankshares, Inc.

HONESDALE, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) — Norwood Financial Corp (NASDAQ Global Market: NWFL), the holding company for Wayne Bank, announced that it has received final regulatory approvals for its proposed acquisition of PB Bankshares, Inc. (“PB Bankshares”) and its wholly owned subsidiary, Presence Bank. [PB Bankshares previously announced on December 11, 2025, that its shareholders approved its proposed merger with Norwood Financial Corp.] Subject to the satisfaction of customary closing conditions, Norwood anticipates closing the acquisition on or about January 5, 2026. Jim Donnelly, President and Chief Executive Officer of Norwood Financial Corp commented “I am proud of the teams of both Presence Bank and Wayne Bank as they are busy working towards the closing of this merger. We expect this combination will allow us...

Continue reading

Sintana Energy Inc. Announces Court Sanction of Scheme of Arrangement and Issue of Shares

TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) — Sintana Energy Inc. (TSX-V: SEI, OTCQX: SEUSF) (“Sintana” or the “Company”) announces that Challenger and Sintana (TSXV:SEI) are pleased to announce that earlier today the recommended acquisition by Sintana of the entire issued and to be issued ordinary share capital of Challenger (the “Acquisition“), to be implemented by way of a Court-sanctioned scheme of arrangement under Part IV (section 152) of the Isle of Man Companies Act 1931 as amended from time to time (the “Scheme”), which was announced by Challenger and Sintana on 9 October 2025, has received approval for the closing of the Acquisition by the TSXV (the “TSXV Condition”), subject to standard post-closing filings, and Sintana has therefore confirmed that the TSXV Condition has now been satisfied and the Scheme has...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.